vaccine
→
HasA
→
adjuvant
|
0.58
|
|
vaccine
→
HasA
→
benefit
|
0.58
|
|
vaccine
→
HasA
→
diphtheria
|
0.55
|
|
vaccine
→
HasA
→
bacteria
|
0.55
|
|
vaccine
→
HasA
→
protein
|
0.54
|
|
vaccine
→
HasA
→
tetanus
|
0.54
|
|
vaccine
→
HasA
→
risk
|
0.53
|
|
vaccine
→
HasA
→
side effects
|
0.51
|
|
vaccine
→
HasA
→
aluminum
|
0.51
|
|
vaccine
→
HasA
→
antigen
|
0.50
|
|
vaccine
→
HasA
→
mercury
|
0.50
|
|
vaccine
→
HasA
→
dna
|
0.49
|
|
vaccine
→
HasA
→
modified live virus
|
0.49
|
|
vaccine
→
HasA
→
acceptable safety profile
|
0.47
|
|
vaccine
→
HasA
→
formaldehyde
|
0.46
|
|
vaccine
→
HasA
→
agent
|
0.46
|
|
vaccine
→
HasA
→
material
|
0.45
|
|
vaccine
→
HasA
→
toxic ingredients
|
0.45
|
|
vaccine
→
HasA
→
monosodium glutamate
|
0.45
|
|
vaccine
→
HasA
→
gelatin
|
0.44
|
|
vaccine
→
HasA
→
thimerosal
|
0.44
|
|
vaccine
→
HasA
→
live virus
|
0.44
|
|
vaccine
→
HasA
→
toxic substances
|
0.44
|
|
vaccine
→
HasA
→
pertussis
|
0.44
|
|
vaccine
→
HasA
→
impact
|
0.44
|
|
vaccine
→
HasA
→
aluminium hydroxide
|
0.43
|
|
vaccine
→
HasA
→
similar components
|
0.42
|
|
vaccine
→
HasA
→
antibody
|
0.42
|
|
vaccine
→
HasA
→
few side effects
|
0.41
|
|
vaccine
→
HasA
→
carcinogen
|
0.40
|
|
vaccine
→
HasA
→
live attenuated viruses
|
0.40
|
|
vaccine
→
HasA
→
low efficacy
|
0.39
|
|
vaccine
→
HasA
→
msg
|
0.39
|
|
vaccine
→
HasA
→
germ
|
0.39
|
|
vaccine
→
HasA
→
substance
|
0.39
|
|
vaccine
→
HasA
→
heavy metals
|
0.39
|
|
vaccine
→
HasA
→
neurotoxin
|
0.39
|
|
vaccine
→
HasA
→
rna
|
0.39
|
|
vaccine
→
HasA
→
thiomersal
|
0.39
|
|
vaccine
→
HasA
→
toxin
|
0.38
|
|
vaccine
→
HasA
→
preservative
|
0.38
|
|
vaccine
→
HasA
→
cell
|
0.38
|
|
vaccine
→
HasA
→
diphtheria and tetanus toxoids
|
0.37
|
|
vaccine
→
HasA
→
foreign dna
|
0.37
|
|
vaccine
→
HasA
→
same effect
|
0.37
|
|
vaccine
→
HasA
→
tetanus toxoid
|
0.36
|
|
vaccine
→
HasA
→
squalene
|
0.35
|
|
vaccine
→
HasA
→
ingredient
|
0.35
|
|
vaccine
→
HasA
→
aluminum adjuvants
|
0.35
|
|
vaccine
→
HasA
→
autism
|
0.34
|
|
vaccine
→
HasA
→
toxoid
|
0.34
|
|
vaccine
→
HasA
→
additive
|
0.34
|
|
vaccine
→
HasA
→
egg protein
|
0.34
|
|
vaccine
→
HasA
→
antibiotic
|
0.34
|
|
vaccine
→
HasA
→
polysorbate
|
0.33
|
|
vaccine
→
HasA
→
little effect
|
0.33
|
|
vaccine
→
HasA
→
the power
|
0.33
|
|
vaccine
→
HasA
→
neomycin
|
0.33
|
|
vaccine
→
HasA
→
protective effect
|
0.32
|
|
vaccine
→
HasA
→
genetic material
|
0.31
|
|
vaccine
→
HasA
→
more benefit
|
0.31
|
|
vaccine
→
HasA
→
polysaccharide
|
0.31
|
|
vaccine
→
HasA
→
adverse effects
|
0.31
|
|
vaccine
→
HasA
→
limited shelf life
|
0.31
|
|
vaccine
→
HasA
→
disease
|
0.30
|
|
vaccine
→
HasA
→
virus
|
0.30
|
|
vaccine
→
HasA
→
aborted fetal tissue
|
0.29
|
|
vaccine
→
HasA
→
little
|
0.29
|
|
vaccine
→
HasA
→
excellent safety record
|
0.29
|
|
vaccine
→
HasA
→
phenoxyethanol
|
0.28
|
|
vaccine
→
HasA
→
dead viruses
|
0.27
|
|
vaccine
→
HasA
→
small amounts of egg protein
|
0.27
|
|
vaccine
→
HasA
→
positive impact
|
0.26
|
|
vaccine
→
HasA
→
live bacteria
|
0.25
|
|
vaccine
→
HasA
→
negative side effects
|
0.25
|
|
vaccine
→
HasA
→
residual
|
0.25
|
|
vaccine
→
HasA
→
thimerasol
|
0.25
|
|
vaccine
→
HasA
→
gmo
|
0.24
|
|
vaccine
→
HasA
→
adjuvant additive
|
0.24
|
|
vaccine
→
HasA
→
nanoparticle
|
0.24
|
|
vaccine
→
HasA
→
preservative thimerosal
|
0.23
|
|
vaccine
→
HasA
→
antifreeze
|
0.23
|
|
vaccine
→
HasA
→
contaminant
|
0.23
|
|
vaccine
→
HasA
→
human fetal cells
|
0.23
|
|
vaccine
→
HasA
→
mycoplasma
|
0.23
|
|
vaccine
→
HasA
→
same antigens
|
0.23
|
|
vaccine
→
HasA
→
tiny fraction of the antigens
|
0.23
|
|
vaccine
→
HasA
→
attenuated viruses
|
0.23
|
|
vaccine
→
HasA
→
the greatest impact
|
0.11
|
|